Financials data is unavailable for this security.
View more
Year on year Novoprotein Scientific Inc 's revenues fell -42.09% from 264.55m to 153.19m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 90.72m to 12.84m, a -85.84% decrease.
Gross margin | 64.49% |
---|---|
Net profit margin | -6.10% |
Operating margin | -14.87% |
Return on assets | -0.37% |
---|---|
Return on equity | -0.39% |
Return on investment | -0.38% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Novoprotein Scientific Inc fell by 65.65m. However, the company earned 69.16m from its operations for a Cash Flow Margin of 45.15%. In addition the company used 81.42m on investing activities and also paid 53.93m in financing cash flows.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 30.65 |
---|---|
Tangible book value per share | 30.39 |
More ▼
Balance sheet in CNYView more
Current ratio | 23.75 |
---|---|
Quick ratio | 22.83 |
Total debt/total equity | 0.0352 |
---|---|
Total debt/total capital | 0.034 |
More ▼